Single-cell and spatial omics unravel the spatiotemporal biology of tumour border invasion and haematogenous metastasis

Abstract

Solid tumours exhibit a well-defined architecture, comprising a differentiated core and a dynamic border that interfaces with the surrounding tissue. This border, characterised by distinct cellular morphology and molecular composition, serves as a critical determinant of the tumour’s invasive behaviour. Notably, the invasive border of the primary tumour represents the principal site for intravasation of metastatic cells. These cells, known as circulating tumour cells (CTCs), function as ‘seeds’ for distant dissemination and display remarkable heterogeneity. Advancements in spatial sequencing technology are progressively unveiling the spatial biological features of tumours. However, systematic investigations specifically targeting the characteristics of the tumour border remain scarce. In this comprehensive review, we illuminate key biological insights along the tumour body-border-haematogenous metastasis axis over the past five years. We delineate the distinctive landscape of tumour invasion boundaries and delve into the intricate heterogeneity and phenotype of CTCs, which orchestrate haematogenous metastasis. These insights have the potential to explain the basis of tumour invasion and distant metastasis, offering new perspectives for the development of more complex and precise clinical interventions and treatments.

Keywords

circulating tumour cell / single-cell sequencing / spatial sequencing / tumour boundary / tumour cell behaviour / tumour microenvironment

References

[1] Fujii M, Sekine S, Sato T. Decoding the basis of histological variation in human cancer. Nat Rev Cancer. 2024; 24: 141-158.

[2] Koch C, Kuske A, Joosse SA, et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med. 2020; 12: e11908.

[3] Zhang L, Ridgway LD, Wetzel MD, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013; 5:180ra148.

[4] Teltsh O, Porgador A, Rubin E. Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome. Oncotarget. 2015; 6: 33191-33205.

[5] Saunus JM, Quinn MC, Patch AM, et al. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol. 2015; 237: 363-378.

[6] Richards S. It’s more than stamp collecting: how genome sequencing can unify biological research. Trends Genet. 2015; 31: 411-421.

[7] Thalgott M, Heck MM, Eiber M, et al. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy. J Cancer Res Clin Oncol. 2015; 141: 1457-1464.

[8] Van der Auwera I, Peeters D, Benoy IH, et al. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer. 2010; 102: 276-284.

[9] Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. 2023; 24: 494-515.

[10] Casasent AK, Schalck A, Gao R, et al. Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell. 2018; 172: 205-217. e212.

[11] Zhao T, Chiang ZD, Morriss JW, et al. Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. Nature. 2022; 601: 85-91.

[12] Chen JH, Nieman LT, Spurrell M, et al. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nat Immunol. 2024; 25: 644-658.

[13] Eng CL, Lawson M, Zhu Q, et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature. 2019; 568: 235-239.

[14] Magen A, Hamon P, Fiaschi N, et al. Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med. 2023; 29: 1389-1399.

[15] Lee JH, Daugharthy ER, Scheiman J, et al. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat Protoc. 2015; 10: 442-458.

[16] Lomakin A, Svedlund J, Strell C, et al. Spatial genomics maps the structure, nature and evolution of cancer clones. Nature. 2022; 611: 594-602.

[17] Rodriques SG, Stickels RR, Goeva A, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019; 363: 1463-1467.

[18] Madissoon E, Oliver AJ, Kleshchevnikov V, et al. A spatially resolved atlas of the human lung characterizes a gland-associated immune niche. Nat Genet. 2023; 55: 66-77.

[19] Oliveira MF, Romero JP, Chung M, et al. Characterization of immune cell populations in the tumor microenvironment of colorectal cancer using high definition spatial profiling. bioRxiv 2024:2024.2006.2004.597233.

[20] Janesick A, Shelansky R, Gottscho AD, et al. High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis. Nat Commun. 2023; 14: 8353.

[21] Galeano Nino JL, Wu H, LaCourse KD, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022; 611: 810-817.

[22] Karras P, Bordeu I, Pozniak J, et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature. 2022; 610: 190-198.

[23] Giesen C, Wang HA, Schapiro D, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014; 11: 417-422.

[24] Keren L, Bosse M, Thompson S, et al. MIBI-TOF: a multiplexed imaging platform relates cellular phenotypes and tissue structure. Sci Adv. 2019; 5: eaax5851.

[25] Gerdes MJ, Sevinsky CJ, Sood A, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A. 2013; 110: 11982-11987.

[26] Du Z, Lin JR, Rashid R, et al. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nat Protoc. 2019; 14: 2900-2930.

[27] Gut G, Herrmann MD, Pelkmans L. Multiplexed protein maps link subcellular organization to cellular states. Science. 2018; 361: eaar7042.

[28] Schubert W, Bonnekoh B, Pommer AJ, et al. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat Biotechnol. 2006; 24: 1270-1278.

[29] van den Brand M, Hoevenaars BM, et al. Sequential immunohistochemistry: a promising new tool for the pathology laboratory. Histopathology. 2014; 65: 651-657.

[30] Schurch CM, Bhate SS, Barlow GL, et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell. 2020; 182: 1341-1359. e1319.

[31] Saka SK, Wang Y, Kishi JY, et al. Immuno-SABER enables highly multiplexed and amplified protein imaging in tissues. Nat Biotechnol. 2019; 37: 1080-1090.

[32] Prentice BM, McMillen JC, Caprioli RM. Multiple TOF/TOF events in a single laser shot for multiplexed lipid identifications in MALDI imaging mass spectrometry. Int J Mass Spectrom. 2019; 437: 30-37.

[33] Wiseman JM, Ifa DR, Zhu Y, et al. Desorption electrospray ionization mass spectrometry: imaging drugs and metabolites in tissues. Proc Natl Acad Sci U S A. 2008; 105: 18120-18125.

[34] He J, Sun C, Li T, et al. A sensitive and wide coverage ambient mass spectrometry imaging method for functional metabolites based molecular histology. Adv Sci (Weinh). 2018; 5: 1800250.

[35] Boxer SG, Kraft ML, Weber PK. Advances in imaging secondary ion mass spectrometry for biological samples. Annu Rev Biophys. 2009; 38: 53-74.

[36] Hou Y, Guo H, Cao C, et al. Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas. Cell Res. 2016; 26: 304-319.

[37] Schwartz GW, Zhou Y, Petrovic J, et al. TooManyCells identifies and visualizes relationships of single-cell clades. Nat Methods. 2020; 17: 405-413.

[38] Cao J, Spielmann M, Qiu X, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019; 566: 496-502.

[39] Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021; 12: 1088.

[40] Nichterwitz S, Chen G, Aguila Benitez J, et al. Laser capture microscopy coupled with Smart-seq2 for precise spatial transcriptomic profiling. Nat Commun. 2016; 7: 12139.

[41] Stahl PL, Salmen F, Vickovic S, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016; 353: 78-82.

[42] Dhainaut M, Rose SA, Akturk G, et al. Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell. 2022; 185: 1223-1239. e1220.

[43] Ravi VM, Will P, Kueckelhaus J, et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell. 2022; 40: 639-655. e613.

[44] Erickson A, He M, Berglund E, et al. Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature. 2022; 608: 360-367.

[45] Tarabichi M, Salcedo A, Deshwar AG, et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat Methods. 2021; 18: 144-155.

[46] Fu X, Zhao Y, Lopez JI, et al. Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nat Ecol Evol. 2022; 6: 88-102.

[47] Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023; 41: 404-420.

[48] Zahir N, Sun R, Gallahan D, Gatenby RA, Curtis C. Characterizing the ecological and evolutionary dynamics of cancer. Nat Genet. 2020; 52: 759-767.

[49] Seferbekova Z, Lomakin A, Yates LR, Gerstung M. Spatial biology of cancer evolution. Nat Rev Genet. 2023; 24: 295-313.

[50] Noble R, Burri D, Le Sueur C, et al. Spatial structure governs the mode of tumour evolution. Nat Ecol Evol. 2022; 6: 207-217.

[51] Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017; 376: 2109-2121.

[52] Sun Y, Wu P, Zhang Z, et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell. 2024; 42: 135-156. e117.

[53] Nguyen B, Fong C, Luthra A, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25, 000 patients. Cell. 2022; 185: 563-575. e511.

[54] Martinez-Jimenez F, Movasati A, Brunner SR, et al. Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature. 2023; 618: 333-341.

[55] Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-892.

[56] Liu X, Zhang K, Kaya NA, et al. Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in hepatocellular carcinoma. Nat Commun. 2024; 15: 3169.

[57] Ge G, Han Y, Zhang J, et al. Single-cell RNA-seq reveals a developmental hierarchy super-imposed over subclonal evolution in the cellular ecosystem of prostate cancer. Adv Sci (Weinh). 2022; 9: e2105530.

[58] Coudray N, Ocampo PS, Sakellaropoulos T, et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018; 24: 1559-1567.

[59] Loeffler CML, Ortiz Bruechle N, Jung M, et al. Artificial intelligence-based detection of FGFR3 mutational status directly from routine histology in bladder cancer: a possible preselection for molecular testing? Eur Urol Focus. 2022; 8: 472-479.

[60] Sundar R, Liu DH, Hutchins GG, et al. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut. 2021; 70: 1823-1832.

[61] Arthur DW, Winter KA, Kuerer HM, et al. Effectiveness of breast-conserving surgery and 3-dimensional conformal partial breast reirradiation for recurrence of breast cancer in the ipsilateral breast: the NRG Oncology/RTOG 1014 Phase 2 clinical trial. JAMA Oncol. 2020; 6: 75-82.

[62] Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019; 394: 2155-2164.

[63] Deryugina EI, Kiosses WB. Intratumoral cancer cell intravasation can occur independent of invasion into the adjacent stroma. Cell Rep. 2017; 19: 601-616.

[64] Zlobec I, Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol. 2009; 15: 5898-5906.

[65] Sun X, Wu B, Chiang HC, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 2021; 599: 673-678.

[66] Davidson S, Efremova M, Riedel A, et al. Single-cell RNA sequencing reveals a dynamic stromal niche that supports tumor growth. Cell Rep. 2020; 31: 107628.

[67] Wu F, Zhang X, Wang M, et al. Deciphering the role of immunoglobulin secreting malignant lineages in the invasive frontiers of small cell lung cancer by scRNA-seq and spatial transcriptomics analysis. Cell Discov. 2023; 9: 123.

[68] Nirmal AJ, Maliga Z, Vallius T, et al. The spatial landscape of progression and immunoediting in primary melanoma at single-cell resolution. Cancer Discov. 2022; 12: 1518-1541.

[69] Tora MS, Neill SG, Lakhina Y, et al. Tumor microenvironment in a minipig model of spinal cord glioma. J Transl Med. 2023; 21: 667.

[70] Davis S, Scott C, Oetjen J, et al. Deep topographic proteomics of a human brain tumour. Nat Commun. 2023; 14: 7710.

[71] Xun Z, Ding X, Zhang Y, et al. Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis. Nat Commun. 2023; 14: 933.

[72] Danenberg E, Bardwell H, Zanotelli VRT, et al. Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat Genet. 2022; 54: 660-669.

[73] Du Y, Shi J, Wang J, et al. Integration of pan-cancer single-cell and spatial transcriptomics reveals stromal cell features and therapeutic targets in tumor microenvironment. Cancer Res. 2024; 84: 192-210.

[74] Liu Y, Xun Z, Ma K, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023; 78: 770-782.

[75] Wu R, Guo W, Qiu X, et al. Comprehensive analysis of spatial architecture in primary liver cancer. Sci Adv. 2021; 7: eabg3750.

[76] Fan G, Xie T, Li L, Tang L, Han X, Shi Y. Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma. NPJ Precis Oncol. 2024; 8: 75.

[77] Schmassmann P, Roux J, Dettling S, et al. Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation. Elife. 2023; 12: RP92678.

[78] Chen Z, Soifer I, Hilton H, Keren L, Jojic V. Modeling multiplexed images with spatial-LDA reveals novel tissue microenvironments. J Comput Biol. 2020; 27: 1204-1218.

[79] He S, Jin Y, Nazaret A, et al. Starfysh integrates spatial transcriptomic and histologic data to reveal heterogeneous tumor-immune hubs. Nat Biotechnol. 2024.

[80] Ruf B, Bruhns M, Babaei S, et al. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Cell. 2023; 186: 3686-3705. e3632.

[81] Zheng B, Wang D, Qiu X, et al. Trajectory and functional analysis of PD-1(high) CD4(+)CD8(+) T cells in hepatocellular carcinoma by single-cell cytometry and transcriptome sequencing. Adv Sci (Weinh). 2020; 7: 2000224.

[82] Qi J, Sun H, Zhang Y, et al. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun. 2022; 13: 1742.

[83] Ozato Y, Kojima Y, Kobayashi Y, et al. Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer. Cell Rep. 2023; 42: 111929.

[84] Wu L, Yan J, Bai Y, et al. An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte-tumor cell crosstalk, local immunosuppression and tumor progression. Cell Res. 2023; 33: 585-603.

[85] Yofe I, Shami T, Cohen N, et al. Spatial and temporal mapping of breast cancer lung metastases identify TREM2 macrophages as regulators of the metastatic boundary. Cancer Discov. 2023; 13: 2610-2631.

[86] Altunbulakli C, Jimenez DG, Askmyr D, et al. Targeted spatial proteomic analysis of CD8(+) T-and myeloid cells in tonsillar cancer. Front Oncol. 2023; 13: 1253418.

[87] Yan X, Xie Y, Yang F, et al. Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis. J Exp Clin Cancer Res. 2021; 40: 142.

[88] Hu H, Piotrowska Z, Hare PJ, et al. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021; 39: 1531-1547. e1510.

[89] Chhabra Y, Weeraratna AT. Fibroblasts in cancer: unity in heterogeneity. Cell. 2023; 186: 1580-1609.

[90] Baessler A, Vignali DAA. T cell exhaustion. Annu Rev Immunol. 2024; 42(1): 179-206.

[91] Miggelbrink AM, Jackson JD, Lorrey SJ, et al. CD4 T-cell exhaustion: does it exist and what are its roles in cancer? Clin Cancer Res. 2021; 27: 5742-5752.

[92] Liu C, Lan Y, Liu B, Zhang H, Hu H. T cell development: old tales retold by single-cell RNA sequencing. Trends Immunol. 2021; 42: 165-175.

[93] Cunha MT, Gouveia MC, Neto FL, et al. Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis. Br J Cancer. 2024; 130: 242-250.

[94] Blanco-Heredia J, Souza CA, Trincado JL, et al. Converging and evolving immuno-genomic routes toward immune escape in breast cancer. Nat Commun. 2024; 15: 1302.

[95] Barras D, Ghisoni E, Chiffelle J, et al. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma. Sci Immunol. 2024; 9: eadg7995.

[96] Gabriely G, Ma D, Siddiqui S, et al. Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating T cells. iScience. 2021; 24: 103347.

[97] Cheng S, Li Z, Gao R, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021; 184: 792-809. e723.

[98] Barkley D, Moncada R, Pour M, et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet. 2022; 54: 1192-1201.

[99] Zhang L, Li Z, Skrzypczynska KM, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020; 181: 442-459. e429.

[100] Liu Y, Zhang Q, Xing B, et al. Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell. 2022; 40: 424-437. e425.

[101] Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022; 21: 799-820.

[102] Molgora M, Liu YA, Colonna M, Cella M. TREM2: a new player in the tumor microenvironment. Semin Immunol. 2023; 67: 101739.

[103] Ji KY, Kim SM, Yee SM, et al. Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells-2 (TREM2). FASEB J. 2021; 35: e21479.

[104] Binnewies M, Pollack JL, Rudolph J, et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021; 37: 109844.

[105] Zhang Y, Chen H, Mo H, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021; 39: 1578-1593. e1578.

[106] Molgora M, Esaulova E, Vermi W, et al. TREM2 Modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 2020; 182: 886-900. e817.

[107] Shi X, Pang S, Zhou J, et al. Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs. Mol Cancer. 2024; 23: 52.

[108] Long H, Jia Q, Wang L, et al. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. Cancer Cell. 2022; 40: 674-693. e677.

[109] Zhu L, Yu X, Wang L, et al. Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges. Oncogenesis. 2021; 10: 47.

[110] Geldhof V, de Rooij L, Sokol L, et al. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast. Nat Commun. 2022; 13: 5511.

[111] Zhao Q, Molina-Portela MDP, Parveen A, et al. Heterogeneity and chimerism of endothelial cells revealed by single-cell transcriptome in orthotopic liver tumors. Angiogenesis. 2020; 23: 581-597.

[112] Goveia J, Rohlenova K, Taverna F, et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell. 2020; 37: 21-36. e13.

[113] Sharma A, Seow JJW, Dutertre CA, et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell. 2020; 183: 377-394. e321.

[114] Zhou PY, Zhou C, Gan W, et al. Single-cell and spatial architecture of primary liver cancer. Commun Biol. 2023; 6: 1181.

[115] Zeng Q, Mousa M, Nadukkandy AS, et al. Understanding tumour endothelial cell heterogeneity and function from single-cell omics. Nat Rev Cancer. 2023; 23: 544-564.

[116] Huang P, Fan X, Yu H, et al. Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer. J Transl Med. 2023; 21: 94.

[117] Mancini C, Lori G, Pranzini E, Taddei ML. Metabolic challengers selecting tumor-persistent cells. Trends Endocrinol Metab. 2024; 35: 263-276.

[118] Sung JY, Cheong JH. Intercellular communications and metabolic reprogramming as new predictive markers for immunotherapy responses in gastric cancer. Cancer Commun (Lond). 2022; 42: 572-575.

[119] Alexandrov T. Spatial metabolomics: from a niche field towards a driver of innovation. Nat Metab. 2023; 5: 1443-1445.

[120] Wang J, Kunzke T, Prade VM, et al. Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients. Clin Cancer Res. 2022; 28: 2865-2877.

[121] Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023; 8: 70.

[122] Banerjee S, Zare RN, Tibshirani RJ, et al. Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids. Proc Natl Acad Sci U S A. 2017; 114: 3334-3339.

[123] Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis. Nat Cancer. 2024; 5: 16-29.

[124] Randall EC, Lopez BGC, Peng S, et al. Localized metabolomic gradients in patient-derived xenograft models of glioblastoma. Cancer Res. 2020; 80: 1258-1267.

[125] Wang M, Deng C, Yang C, et al. Unraveling temporal and spatial biomarkers of epithelial-mesenchymal transition in colorectal cancer: insights into the crucial role of immunosuppressive cells. J Transl Med. 2023; 21: 794.

[126] Liu YM, Ge JY, Chen YF, et al. Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination. Adv Sci (Weinh). 2023; 10: e2205395.

[127] Fiore VF, Krajnc M, Quiroz FG, et al. Mechanics of a multilayer epithelium instruct tumour architecture and function. Nature. 2020; 585: 433-439.

[128] Du W, Nair P, Johnston A, Wu PH, Wirtz D. Cell trafficking at the intersection of the tumor-immune compartments. Annu Rev Biomed Eng. 2022; 24: 275-305.

[129] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019; 20: 69-84.

[130] Li R, Ferdinand JR, Loudon KW, et al. Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Cancer Cell. 2022; 40: 1583-1599. e1510.

[131] Cao J, Zheng Z, Sun D, et al. Decoder-seq enhances mRNA capture efficiency in spatial RNA sequencing. Nat Biotechnol. 2024.

[132] Fujiyoshi K, Vayrynen JP, Borowsky J, et al. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine. 2020; 57: 102860.

[133] Wei L, Delin Z, Kefei Y, Hong W, Jiwei H, Yange Z. A classification based on tumor budding and immune score for patients with hepatocellular carcinoma. Oncoimmunology. 2020; 9: 1672495.

[134] Zuo L, Li W, You S. Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway. Breast Cancer Res. 2010; 12: R34.

[135] Zhu XL, Wang YL, Chen JP, et al. Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition. Tumour Biol. 2014; 35: 1627-1635.

[136] Zhu X, Zhong J, Zhao Z, et al. Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition. Oncotarget. 2015; 6: 25320-25338.

[137] Pastushenko I, Brisebarre A, Sifrim A, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018; 556: 463-468.

[138] Malagoli Tagliazucchi G, Wiecek AJ, Withnell E, Secrier M. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer. Nat Commun. 2023; 14: 789.

[139] Puram SV, Tirosh I, Parikh AS, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017; 171: 1611-1624. e1624.

[140] Zhang Q, Fei L, Han R, et al. Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma. Cell Discov. 2022; 8: 94.

[141] Morikawa M, Derynck R, Miyazono K. TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016; 8: a021873.

[142] Macias MJ, Martin-Malpartida P, Massague J. Structural determinants of Smad function in TGF-beta signaling. Trends Biochem Sci. 2015; 40: 296-308.

[143] Katsuno Y, Derynck R. Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-beta family. Dev Cell. 2021; 56: 726-746.

[144] Zoni E, van der Pluijm G, Gray PC, Kruithof-de Julio M. Epithelial plasticity in cancer: unmasking a MicroRNA network for TGF-beta-, Notch-, and Wnt-mediated EMT. J Oncol. 2015; 2015: 198967.

[145] Ye Z, Li Q, Hu Y, et al. The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes. Cancer Lett. 2024; 588: 216769.

[146] Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017; 168: 670-691.

[147] Csonti K, Fazakas C, Molnar K, Wilhelm I, Krizbai IA, Vegh AG. Breast adenocarcinoma cells adhere stronger to brain pericytes than to endothelial cells. Colloids Surf B Biointerfaces. 2024; 234: 113751.

[148] Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023; 186: 1564-1579.

[149] Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021; 6: 404.

[150] Limaye S, Chowdhury S, Rohatgi N, et al. Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells. Cancer Med. 2023; 12: 9116-9127.

[151] Sun YF, Wu L, Liu SP, et al. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat Commun. 2021; 12: 4091.

[152] Sun YF, Guo W, Xu Y, et al. circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma. Clin Cancer Res. 2018; 24: 547-559.

[153] Dong X, Ma Y, Zhao X, et al. Spatial heterogeneity in epithelial to mesenchymal transition properties of circulating tumor cells associated with distant recurrence in pancreatic cancer patients. Ann Transl Med. 2020; 8: 676.

[154] Diamantopoulou Z, Castro-Giner F, Schwab FD, et al. The metastatic spread of breast cancer accelerates during sleep. Nature. 2022; 607: 156-162.

[155] Yu T, Wang C, Xie M, et al. Heterogeneity of CTC contributes to the organotropism of breast cancer. Biomed Pharmacother. 2021; 137: 111314.

[156] Huh HD, Sub Y, Oh J, et al. Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination. Mol Cancer. 2023; 22: 63.

[157] Taftaf R, Liu X, Singh S, et al. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nat Commun. 2021; 12: 4867.

[158] Lah TT, Novak M, Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin Cancer Biol. 2020; 60: 262-273.

[159] Cheng YH, Chen YC, Lin E, et al. Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nat Commun. 2019; 10: 2163.

[160] Shaikh MV, Kala M, Nivsarkar M. CD90 a potential cancer stem cell marker and a therapeutic target. Cancer Biomark. 2016; 16: 301-307.

[161] Szczerba BM, Castro-Giner F, Vetter M, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019; 566: 553-557.

[162] Rupp B, Ball H, Wuchu F, Nagrath D, Nagrath S. Circulating tumor cells in precision medicine: challenges and opportunities. Trends Pharmacol Sci. 2022; 43: 378-391.

[163] Liu X, Song J, Zhang H, et al. Immune checkpoint HLA-E:cD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023; 41: 272-287. e279.

[164] van de Haar J, Mankor JM, Hummelink K, et al. Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer. Clin Cancer Res. 2024; 30: 1307-1318.

[165] Stewart CA, Gay CM, Xi Y, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020; 1: 423-436.

[166] Pang S, Xu S, Wang L, et al. Molecular profiles of single circulating tumor cells from early breast cancer patients with different lymph node statuses. Thorac Cancer. 2023; 14: 156-167.

[167] Suvilesh KN, Nussbaum YI, Radhakrishnan V, et al. Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses. Mol Cancer. 2022; 21: 73.

[168] Pailler E, Faugeroux V, Oulhen M, et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer. Clin Cancer Res. 2019; 25: 6671-6682.

[169] Zhang Z, Xu Y. FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF-beta/SMAD3 signaling. Mol Med. 2022; 28: 82.

[170] Fox DB, Ebright RY, Hong X, et al. Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. NPJ Precis Oncol. 2023; 7: 25.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.